Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II

Trial Profile

A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine
  • Indications Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Oct 2018 Planned End Date changed from 4 Apr 2019 to 22 Apr 2019.
    • 20 Jul 2018 Planned End Date changed from 19 Apr 2019 to 4 Apr 2019.
    • 20 Jul 2018 Planned primary completion date changed from 9 Oct 2018 to 3 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top